Insights

Late-stage pipeline Genmab has a strong late-stage clinical pipeline with wholly owned programs, presenting opportunities to partner or co-develop across high-value oncology assets and expand market access through strategic collaborations.

DARZALEX royalties Significant net sales royalties from DARZALEX indicate robust commercial traction and scalable revenue streams that can be leveraged to negotiate favorable collaboration terms, co-promotion, or licensing deals for adjacent antibody therapies.

Innovation leadership Genmab’s expertise in novel antibody formats such as bispecifics and antibody-drug conjugates positions the company as a partner of choice for AI-driven discovery platforms, customization of manufacturing services, or joint development programs that require advanced modality capabilities.

Global footprint With a strong international presence across North America, Europe, and Asia Pacific, there are opportunities to explore regional partnerships, supply chain enhancements, and market-entry arrangements to accelerate global commercialization.

Clinical momentum Positive Phase 3 results in hematologic indications like frontline DLBCL create upside for expanded indications and competitive positioning, suggesting sales plays around lifecycle management, label expansions, and payer-focused reimbursement strategies.

Similar companies to Genmab

Genmab Tech Stack

Genmab uses 8 technology products and services including Adobe Analytics, Microsoft Power Apps, Qlik, and more. Explore Genmab's tech stack below.

Media & News

Genmab's Email Address Formats

Genmab uses at least 4 email formats:
Genmab Email FormatsExamplePercentage
F.Last@genmab.comJ.Doe@genmab.com
56%
LastFirst@genmab.comDoeJohn@genmab.com
25%
FirstL@genmab.comJohnD@genmab.com
13%
FiLast@genmab.comJoDoe@genmab.com
6%

Frequently Asked Questions

What is Genmab's phone number?

Minus sign iconPlus sign icon
You can contact Genmab's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Genmab's stock symbol?

Minus sign iconPlus sign icon
Genmab is a publicly traded company; the company's stock symbol is GMAB.

What is Genmab's official website and social media links?

Minus sign iconPlus sign icon
Genmab's official website is genmab.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Genmab generate?

Minus sign iconPlus sign icon
As of October 2026, Genmab's annual revenue is estimated to be $1B - $10B.

What is Genmab's SIC code and NAICS code?

Minus sign iconPlus sign icon
Genmab's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Genmab have currently?

Minus sign iconPlus sign icon
As of October 2026, Genmab has approximately 3.1K employees across 6 continents, including Europe, North America and Asia. Key team members include Cpo, Head Of Pharmaceutical Affairs: A. E., Vice President Clinical Research: M. S. and Vice President Cmc, Head Of New Product Introduction: C. C. Explore Genmab's employee directory with LeadIQ.

What industry does Genmab belong to?

Minus sign iconPlus sign icon
Genmab operates in the Biotechnology Research industry.

What technology does Genmab use?

Minus sign iconPlus sign icon
Genmab's tech stack includes Adobe Analytics, Microsoft Power Apps, Qlik, DBT, PostgreSQL, Amazon Simple Email Service, ADP Workforce Now and SuccessFactors.

What is Genmab's email format?

Minus sign iconPlus sign icon
Genmab's email format typically follows the pattern of F.Last@genmab.com. Find more Genmab email formats with LeadIQ.

How much funding has Genmab raised to date?

Minus sign iconPlus sign icon
As of October 2026, Genmab has raised $12B in funding. The last funding round occurred on Nov 18, 2025 for $5.5B.
Genmab logo

Genmab

Biotechnology ResearchHovedstaden, Denmark1001-5000 Employees

Genmab is an international biotechnology company focused on developing antibody medicines to improve outcomes for people with cancer and other serious diseases. The company is advancing a substantial late-stage clinical pipeline with wholly owned programs, seeking to deliver transformative medicines to patients. Headquartered in Copenhagen, Denmark, Genmab has a broad international footprint across North America, Europe, and the Asia Pacific region.

Its primary customers are patients and clinicians seeking new cancer therapies, as well as health systems that support delivery of advanced treatments. In June 2026, Genmab reported data from studies of epcoritamab in first-line diffuse large B-cell lymphoma, noting high response rates in elderly patients.

Section iconCompany Overview

Phone number
Website
genmab.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
GMAB
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
1001-5000

Section iconFunding & Financials

  • $12B

    Genmab has raised a total of $12B of funding over 7 rounds. Their latest funding round was raised on Nov 18, 2025 in the amount of $5.5B as a Post IPO Debt.

  • $1B - $10B

    Genmab's revenue is estimated to be in the range of $1B - $10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.